Momenta Pharmaceuticals, Inc. (MNTA)

[pollyvonwog]

Perhaps a reason for the weakness yesterday:
Teva Patent Case Likely to Be Sent Back to Federal Circuit: Citi

Friday, October 10, 2014 05:02 AM
by Catherine Larkin
Oct. 10 (Bloomberg) -- Teva faces >60% odds that U.S. Supreme Court will send invalidated Copaxone 20mg patent back to Federal Circuit for reevaluation under new legal standard, Citi analyst Liav Abraham (buy, PT $70) says in note yday.

Implies further delay to resolution of case, would give Teva more time to switch patients to longer-acting 40mg dose
Citi expects ruling in early 2015; generic cos. unlikely to pursue “at-risk” sales before IP resolution, would be liable for substantial damages if patent ultimately upheld by courts
Base case model assumes generic approval, introduction in 1Q15
NOTE: Supreme Court will hear Copaxone case Oct. 15